The ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis agentshould beinitiated withneratinib for thefirst 8 weeksThe onlysteroidalaromataseinhibitor in itsdrug classThis treatmentmodality isalwayscombined withlumpectomysurgeryThis drugclass are thebackbone ofHR+ diseaseThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trial1%This agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression I can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab dosePreferredregimen forHR+ diseasefor frail/elderlypatientsPreferredfrequencyof GnRHagonistsThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabDuration of timepatients willtakeabemaciclib inearly stagediseasePatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This agent cancauseendometrialcancer, but hasbone densityprotective effectThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Based onOncotype DX,a score of 35will receivethis treatmentThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis agentshould beinitiated withneratinib for thefirst 8 weeksThe onlysteroidalaromataseinhibitor in itsdrug classThis treatmentmodality isalwayscombined withlumpectomysurgeryThis drugclass are thebackbone ofHR+ diseaseThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trial1%This agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression I can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab dosePreferredregimen forHR+ diseasefor frail/elderlypatientsPreferredfrequencyof GnRHagonistsThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabDuration of timepatients willtakeabemaciclib inearly stagediseasePatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This agent cancauseendometrialcancer, but hasbone densityprotective effectThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Based onOncotype DX,a score of 35will receivethis treatment

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  2. This agent should be initiated with neratinib for the first 8 weeks
  3. The only steroidal aromatase inhibitor in its drug class
  4. This treatment modality is always combined with lumpectomy surgery
  5. This drug class are the backbone of HR+ disease
  6. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  7. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  8. 1%
  9. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  10. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  11. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  12. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  13. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  14. Preferred regimen for HR+ disease for frail/elderly patients
  15. Preferred frequency of GnRH agonists
  16. This agent can be added to LN+ HER2+ disease given with trastuzumab
  17. Duration of time patients will take abemaciclib in early stage disease
  18. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  19. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  20. Patients with HER2+ disease continue targeted therapy for this duration
  21. This subtype of breast cancer has the lowest relative 5-year survival rate
  22. This agent can cause endometrial cancer, but has bone density protective effect
  23. This should be monitored routinely every 3-4 months while receiving trastuzumab
  24. Based on Oncotype DX, a score of 35 will receive this treatment